TAS-102, an oral combination of trifluridine and tipiracil hydrochloride, met its primary endpoint of overall survival in the Phase III RECOURSE trial. The product increased the lifespan of patients with refractory mCRC whose disease had progressed after…
written on 13.05.2014
Taiho to file colorectal cancer combo following positive PhIII data
